Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/neiHMJOLC6 https://t.co/odWKphoV7j
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Mentions
Extended reach
Total likes
Video views
Mentions per month
May 2019 – Feb 2025Where it's discussed
-
X / Twitter162 posts
-
News18 articles
-
Facebook16 posts
-
Blogs4 articles
-
YouTube3 videos
AI synopsis
What people are saying
In the discussions, many commenters pointed out that dabigatran did not demonstrate superiority to aspirin in preventing recurrent strokes, referencing the RE-SPECT ESUS trial. Phrases like 'dabigatran was not superior' and 'no benefit of DOAC in ESUS' suggest a critical tone towards previous assumptions about dabigatran's efficacy. The choice of words and the tone of certainty convey a shared understanding that these results are pivotal for clinical guidelines.
The discussions largely reflect a consensus that dabigatran is not superior to aspirin, leading to general agreement on the article's conclusions.
Many participants showcased high interest, as evident from the active interchange and references to related trials.
There is a moderate level of engagement with users discussing study specifics and raising questions about implications.
Participants overwhelmingly perceive the findings as impactful for clinical practice, indicating that the results could influence treatment decisions.
Abstract in brief
- Cryptogenic strokes make up 20-30% of ischemic strokes, often caused by embolisms from unknown sources, and previous studies found rivaroxaban equal to aspirin in preventing recurrent strokes.
- A multicenter trial assessed dabigatran (150 mg or 110 mg) versus aspirin (100 mg) in preventing recurrent strokes among 5,390 patients, focusing on stroke recurrence and major bleeding as outcomes.
- Results showed dabigatran did not significantly outperform aspirin in preventing recurrent strokes, with similar rates of major bleeding in both groups, indicating no clear advantage of dabigatran over aspirin for this patient population.
Top posts
Most liked on X and BlueskyTrending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://t.co/IfAnDzliu1
#WeekendLecture #ESUS Benefits from #anticoagulation hypothesis was studied in 2 RCT
Dabigatran versus aspirin for embolic stroke of undetermined source (ESUS). The final verdict is marginally in favour of aspirin https://t.co/jebqgxyHNL https://t.co/lxlJtYp6wf
In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke and there were more clinically relevant nonmajor bleeding events in the dabigatran group. https://t.co/wFBR5yOUWm
Results from RE-SPECT ESUS trial out now with co-head of stroke theme @vthijs https://t.co/ouKMH4PuSc https://t.co/xjOaJxNB33
All mentions
AF Ablation Trials and Stroke Prevention Insights
This week, John Mandrola MD discusses important findings from recent AF ablation trials and emphasizes the significance of RCTs, particularly in the context of cryptogenic strokes. He reviews the comparative…
Cerebral Embolism and Antithrombotic Strategies in AF and CAD
Silent cerebral embolism and antithrombotic strategies in patients with AF and CAD are the focus of this podcast featuring John Mandrola MD. Explore the implications of recent studies on stroke prevention and management…
Analyzing Stroke Prevention in Cryptogenic Stroke Patients
This episode discusses the efficacy of dabigatran versus aspirin in preventing recurrent strokes among patients with cryptogenic strokes. Recent trial results show no significant advantage of dabigatran over aspirin…
2/4 …series of trials, beginning with rivaroxaban (https://t.co/91EedGQx17) in 2018, then dabigatran (https://t.co/ScOtOHPrtp) in 2019 found that neither drug was superior to aspirin. Now we have apixaban, which also failed to show any benefit over aspirin. They added a twist,
@Gustavo22205004 @LorenVillato Sus palabras son incorrectas. Hay más indicaciones en las que los ACOD han fallado que en las que han resultado. Le dejo algo de bibliografía por si desea documentarse. Un saludo: https://t.co/HvrqGCsKrO https://t.co/rGEo5QFyZQ https://t.co/DKig2sFT0z https://t.co/aOwEbRgnfO
@AguilarMolina_ @jsenior64 @gonzaeperez @adribaran @SposatoL El ⚖️ entre el
RT @NEJM: #VisualAbstract: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://…
RT @WorldStrokeEd: #WeekendLecture #ESUS Benefits from #anticoagulation hypothesis was studied in 2 RCT
RT @WorldStrokeEd: #WeekendLecture #ESUS Benefits from #anticoagulation hypothesis was studied in 2 RCT
#WeekendLecture #ESUS Benefits from #anticoagulation hypothesis was studied in 2 RCT
.@drsuneet taling about #AFib and #ESUS - unfortunately both NAVIGATE-ESUS and RESPECT-ESUS did not show benefit of #DOAC in this population. NAVIGATE-ESUS (Rivaroxaban): https://t.co/98s5NjhlJn RESPECT-ESUS (Dabigatran): https://t.co/MuuKmmNvrC #WAfib2021 https://t.co/XD9R4zYz0K
RE-SPECT ESUS Trial Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://t.co/KQ6T0NQMJT https://t.co/5RFMCJecZg
RT @mfmuri: No benefit of DOAC in ESUS #ElectroSIAC Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source |…
RT @mfmuri: No benefit of DOAC in ESUS #ElectroSIAC Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source |…
RT @netta_doc: Important papers to reference - both NAVIGATE-ESUS and RESPECT-ESUS re: #anticoagulation & embolic stroke of undetermined so…
Important papers to reference - both NAVIGATE-ESUS and RESPECT-ESUS re: #anticoagulation & embolic stroke of undetermined source: NAVIGATE-ESUS: https://t.co/nQv4jSUbBd RESPECT-ESUS: https://t.co/MuuKmmNvrC #WAFib2020 https://t.co/wh8goB2pOg https://t.co/9FhuBCQbPw
RT @PittStroke: @DrAltschul @YoungNir @StrokeAHA_ASA @NEJM @TheLancet @svinsociety @JNISEditor @JNIS_BMJ @American_Stroke @SurviveStroke Pr…
@DrAltschul @YoungNir @StrokeAHA_ASA @NEJM @TheLancet @svinsociety @JNISEditor @JNIS_BMJ @American_Stroke @SurviveStroke Prevention: 21 days of DAPT (https://t.co/OM32DnHakH) RESPECT-ESUS (https://t.co/QVddCVstBA)
RT @StrokeAHA_ASA: RE-SPECT Dabigatran in ESUS? https://t.co/jE71gpHQMb In this new #BloggingStroke post, Grace Y. Kuo discusses @NEJM arti…
RT @StrokeAHA_ASA: RE-SPECT Dabigatran in ESUS? https://t.co/jE71gpHQMb In this new #BloggingStroke post, Grace Y. Kuo discusses @NEJM arti…
RE-SPECT Dabigatran in ESUS? https://t.co/jE71gpHQMb In this new #BloggingStroke post, Grace Y. Kuo discusses @NEJM article "Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source" https://t.co/LWvoenoqx0
Trend up+16: *Diener HC* et al (N Engl J Med) __Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.__ https://t.co/CqVw77OCIC
ECV Isquemico. Usar solo ASA. No Dabigatran https://t.co/jkrV9jQInH
Trend up+4: *Diener HC* et al (N Engl J Med) __Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.__ https://t.co/CqVw77OCIC
Trend up+1: *Diener HC* et al (N Engl J Med) __Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.__ https://t.co/CqVw77OCIC
Trend up+7: *Diener HC* et al (N Engl J Med) __Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.__ https://t.co/CqVw77OCIC
#Dabigatran for Prevention of Stroke After Embolic Stroke of Undetermined Source https://t.co/sNzrFjhpsR vía @practiceupdate #Ictus
RT @neurochecklists: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/6NPGHWhxgY
RT @neurochecklists: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/6NPGHWhxgY
RT @neurochecklists: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/6NPGHWhxgY
RT @neurochecklists: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/6NPGHWhxgY
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/6NPGHWhxgY
Dabigatran for Prevention of Recurrent Stroke after an Embolic Stroke; During median follow-up of 19 months, incidence of recurrent stroke was not significantly different in the dabigatran and aspirin groups (6.6% and 7.7%, respectively). | NEJM https://t.co/XN4I2C6Xqw
RT @NEJM: #VisualAbstract: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://…
Dabigatran for Prevention of Stroke After Embolic Stroke of Undetermined Source https://t.co/zVPhrTyRfS via @practiceupdate
In a recent study published in the @NEJM, researchers saw that dabigatran was not superior to aspirin in preventing recurrent #stroke–particularly among patients with a recent history of embolic stroke. https://t.co/3RQ48vHFoX
Presumptive anticoagulation for embolic stroke of undetermined source (ESUS) is generally not justified, but specific subgroups may derive benefit. | NEJM https://t.co/hSCV7wjrFi
#EBM EvidenceAlerts | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. https://t.co/q2lIWV4474
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in pre…
RT @jvillacastin: Crees q los resultados de este estudio van influir en la búsqueda con Holter de episodios no sostenidos de fibrilación au…
Crees q los resultados de este estudio van influir en la búsqueda con Holter de episodios no sostenidos de fibrilación auricular (ENSFA)? Si la anticoagulación no disminuye recurrencias en estos pacientes será q no son “trombóticos”? https://t.co/69PPhpq7jE 10.1056/NEJMoa1813959
In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke and there were more clinically relevant nonmajor bleeding events in the dabigatran group. https://t.co/wFBR5yOUWm
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/EwLEGXAcYx via @NEJM #dabigatran #ICTUS https://t.co/7JZ9fMaSqx
Also see this @NEJM article by @DrSaccoNeuro et al: In RE-SPECT ESUS, dabigatran was not superior to aspirin in preventing recurrent stroke in ESUS patients. Moreover, dabigatran group had more clinically relevant nonmajor (but not major) bleeding events. https://t.co/ItsGRblkQF https://t.co/A43L78HNmJ
A recent clinical trial shows that #dabigatran was not superior to #aspirin in preventing recurrent stroke in patients that have a history of cryptogenic strokes. https://t.co/3RQ48vHFoX
Let's #DiscussCLOTPlus:" Dabigatran for Prevention of #Stroke after #Embolic Stroke of Undetermined Source." https://t.co/EHWQWx7zUo https://t.co/rPYqJDT2Ws
ダビガトランのESUS再発予防効果はアスピリンを上回らない ソース不詳の塞栓性脳梗塞(ESUS)患者5,390名を対象としてダビガトランとアスピリンを比較するRCT。一次アウトカムは脳梗塞再発。 一次アウトカムに群間差無し。大出血はダビガトラン群1.7%、アスピリン群1.4%。 https://t.co/cHui7itOuU
Dabigatran is not superior to #aspirin for preventing recurrent cryptogenic stroke. @NEJM https://t.co/jqBjnMRvgV
RT @neurochecklists: Dabigatran versus aspirin for embolic stroke of undetermined source (ESUS). The final verdict is marginally in favour…
RT @neurochecklists: Dabigatran versus aspirin for embolic stroke of undetermined source (ESUS). The final verdict is marginally in favour…
RT @neurochecklists: Dabigatran versus aspirin for embolic stroke of undetermined source (ESUS). The final verdict is marginally in favour…
Dabigatran versus aspirin for embolic stroke of undetermined source (ESUS). The final verdict is marginally in favour of aspirin https://t.co/jebqgxyHNL https://t.co/lxlJtYp6wf
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/Z5DiKJOmUH
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/Qfqsgbrl3X #stroke
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
RT @NEJM: Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.c…
Trending on https://t.co/4NNEmdSsxY: Dabigatran for Prevention of Stroke after Embolic #Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://t.co/IfAnDzliu1
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
Dabigatrán para la prevención del accidente cerebrovascular después de un accidente cerebrovascular de origen indeterminado: el dabigatrán no es superior a la aspirina para prevenir el accidente cerebrovascular recurrente. https://t.co/CnXT3Z0aot
[trend] up+4: *Diener HC* et al (N Engl J Med) **Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.** https://t.co/CqVw77OCIC
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
ESUS後の脳梗塞再発予防にアスピリンとダビガトランの有意差なし。副作用として大出血は変わらないが、非主要出血はダビガトランの方が多いかも。 Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. https://t.co/Xs8jGTUpYJ
RT @jsenior64: Dabigatran was not superior to aspirin in preventing recurrent stroke. https://t.co/z9oM2m9HFW
RT @RevistaMFSamfyc: Dabigatran para la prevención del ictus tras ictus embólico de origen indeterminado https://t.co/fKznRxusyu PMID 31091…
RT @jvillacastin: In P with a recent history of embolic stroke of undetermined source, dabigatran (D) was not superior to aspirin (AAS) in…
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/l90BUktXAt
RT @tsengeric: Dabigatran did not significantly reduce risk of recurrent stroke compared with aspirin in patients with embolic stroke of un…
RT @manyooa: Pt: Is dabigatran superior to Aspirin to decrease risk of recurrent embolic stroke events? Dr:In pts w recent history of embol…
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/rZEDHThKs8 #Health #stroke #StrokeCare #aspirin #dabigatran #wellness
Pt: Is dabigatran superior to Aspirin to decrease risk of recurrent embolic stroke events? Dr:In pts w recent history of embolic stroke of unknown source, dabigatran was NON SUPERIOR to aspirin in preventing recurrent stroke. https://t.co/iDqZrK998B
RT @FloreyStroke: Results from RE-SPECT ESUS trial out now with co-head of stroke theme @vthijs https://t.co/ouKMH4PuSc https://t.co/xjOaJx…
RT @FloreyStroke: Results from RE-SPECT ESUS trial out now with co-head of stroke theme @vthijs https://t.co/ouKMH4PuSc https://t.co/xjOaJx…
Dabigatran in full dose was only as effective as aspirin in stopping recurrent cryptogenic stroke in Sinus Rhythm https://t.co/Edpk3vqdtZ
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. https://t.co/XvSuz6Pciq
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/seOVbHCBzX
No benefit of DOAC in ESUS #ElectroSIAC Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/AJYbk7ehjy
Results from RE-SPECT ESUS trial out now with co-head of stroke theme @vthijs https://t.co/ouKMH4PuSc https://t.co/xjOaJxNB33
RT @StrokeAHA_ASA: INTERVIEW: #BloggingStroke contributor Aristeidis H. Katsanos interviews Professor Dr. Hans-Christoph Diener on “Dabigat…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
For patients with a recent history of embolic #stroke of unknown etiology, dabigatran was no better than aspirin in recurrent stroke prevention @NEJM https://t.co/Tfh5IkkNeo #StrokeMonth
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @StrokeAHA_ASA: INTERVIEW: #BloggingStroke contributor Aristeidis H. Katsanos interviews Professor Dr. Hans-Christoph Diener on “Dabigat…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
INTERVIEW: #BloggingStroke contributor Aristeidis H. Katsanos interviews Professor Dr. Hans-Christoph Diener on “Dabigatran for Prevention of #Stroke after Embolic Stroke of Undetermined Source,” published in @NEJM https://t.co/hZTTz8kFWW https://t.co/Jvlx4rWUOk
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: #VisualAbstract: The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran with those of aspirin for the prevention…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source | NEJM https://t.co/RUPnLBfUtK
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
RT @NEJM: Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/ne…
Original Article: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (RE-SPECT ESUS) https://t.co/neiHMJOLC6 https://t.co/odWKphoV7j
RT @NEJM: #VisualAbstract: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://…
RT @NEJM: #VisualAbstract: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://t.co/neiHMJOLC6 https://…